GTX medical BV (GTX) and NeuroRecovery Technologies have announced they have merged to create a company committed to developing novel neuromodulation therapies to improve functional recovery of people with spinal cord injuries; the merged entity will be known as GTX medical BV. Furthermore, the Christopher & Dana Reeve Foundation—a non-profit organisation dedicated to advancing innovative research and improving quality of life for people living with paralysis—will be a shareholder in the merged company.
A press release reports that Ian Curtis, board member of the Reeve Foundation, will join the board of directors of GTX medical BV. It adds that existing investors include LSP, Inkef, Wellington Partners and GIMV.
The merged company, the press release says, is developing targeted epidural spine stimulation (TESS). This is an implantable spinal cord stimulation system that will be designed to provide real-time motion feedback. According to the press release, this system is in late-stage development and has already been shown to restore locomotion in a select number of patients with spinal cord injury. A second, non-invasive product offering—transcutaneous spinal cord stimulation (tSCS)—is being developed to restore upper limb movement and hand function.
The companies will combine their collective scientific and technical expertise, and will continue to collaborate with world-class physicians and clinical scientists to develop other complimentary applications for their technologies to further improve functional recovery and alleviate neurological impairments.
Sjaak Deckers, CEO of GTX, comments: “People with spinal cord injuries deserve a dedicated and coordinated effort of scientists, clinicians and entrepreneurs to bring to market new therapies and products to improve functional outcomes and quality of life. Our combined organisation is dedicated and committed to improving the well-being of these individuals.”
Peter Wilderotter, president and CEO of the Reeve Foundation, comments: “The Reeve Foundation has invested tens of millions of dollars in basic research to get us to this point. We believe discoveries are the moral property of people living with paralysis. This strategic alliance between GTX and NRT will bridge the translational gap that exists between academia and industry to speed the development of vital new treatments and therapies. However, beyond a partnership, it is a promise that is long overdue to the millions living with spinal cord injury worldwide.”
In parallel with this merger, GTX has renewed license agreements with the University of California in Los Angeles, the California Institute of Technology and the University of Louisville, complementing existing license agreements with the École Poly-technique Fédérale de Lausanne, and strengthening the company’s intellectual property portfolio.